AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
17min chapter
Novo Nordisk (Ozempic)
Acquired
Novo Nordisk's Success and Stagnant Stock
This chapter discusses Novo Nordisk's performance in 2015, where they achieved record revenues of $16 billion. However, despite this success, their stock remains stagnant. The chapter also touches on the insulin pricing scandal in the US, where insulin prices were rising and causing public outcry. This, along with the underperformance of a drug called sex-senda, led to a CEO change in 2016 and a significant drop in the company's stock.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode